Alveolar type II cells and pulmonary surfactant in COVID-19 era

Title:

Alveolar type II cells and pulmonary surfactant in COVID-19 era

Creator:

Calkovska, Andrea, Kolomaznik, Maros, and Calkovsky, Vladimir

Identifier:

https://cdk.lib.cas.cz/client/handle/uuid:2ffc8b72-4231-40e1-85de-4c7dae12418a
uuid:2ffc8b72-4231-40e1-85de-4c7dae12418a
doi:10.33549/physiolres.934763

Subject:

pulmonary surfactant, alveolar type II cell, SARS-CoV-2, COVID-19, and ARDS

Type:

model:article and TEXT

Format:

počítač and online zdroj

Description:

In this review, we discuss the role of pulmonary surfactant in the host defense against respiratory pathogens, including novel coronavirus SARS-CoV-2. In the lower respiratory system, the virus uses angiotensin-converting enzyme 2 (ACE2) receptor in conjunction with serine protease TMPRSS2, expressed by alveolar type II (ATII) cells as one of the SARS-CoV-2 target cells, to enter. ATII cells are the main source of surfactant. After their infection and the resulting damage, the consequences may be severe and may include injury to the alveolar-capillary barrier, lung edema, inflammation, ineffective gas exchange, impaired lung mechanics and reduced oxygenation, which resembles acute respiratory distress syndrome (ARDS) of other etiology. The aim of this review is to highlight the key role of ATII cells and reduced surfactant in the pathogenesis of the respiratory form of COVID-19 and to emphasize the rational basis for exogenous surfactant therapy in COVID-19 ARDS patients.

Language:

English

Rights:

http://creativecommons.org/licenses/by-nc-sa/4.0/
policy:public

Coverage:

S195-S208

Source:

Physiological research | 2021 Volume:70 | Number:Supplement 2

Harvested from:

CDK

Metadata only:

false